Aurobindo Pharma Limited    
17 Oct 2017, 09:12PM
757.25
-0.77%
Business Standard
Aurobindo Pharma said the product will be launched immediately
Aurobindo Pharma Limited    
03 Oct 2017
757.25
-0.77%
Business Standard
BS ReporterHyderabad, 3 October: The dwindling anti-retroviral(ARV) contribution to the overall revenues of Aurobindo Pharma is likely to see improvement in the second half of the current financial year as the company expects to launch its new Dolutegravir(DTG) triple combination drug in the sub-Saharan Africa in the third quarter.In August the company had received tentative approval from the US Food and Drug Administration(USFDA) under the US President's Emergency Plan For AIDS Relief (PEPFAR) for its new drug application for dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets. The company is expected to realise the full revenue potential of the product once it gets the final USFDA approval to be able to launch in the US market. Aurobindo considers DTG as the growth driver in the next 3-4 years in ARV segment. According to the company, the triple drug combination product is expected to have a $ 500 million market in 2018. Aurobindo is the first company to sign license .
Number of FIIs/FPIs holding stock rose by 6 to 775 in Sep 2017 qtr.
Aurobindo Pharma Limited    
03 Oct 2017
757.25
-0.77%
Emkay
appears to be the first guidance published where USFDA has taken cognizance of the need to provide a platform for accelerated development of complex generics. The draft seeks to lay a pathway for discussions between the agency and generic filers, both pre and post ANDA filing. Note that the guidance is only a draft with comments invited from companies; a final guidance document will be issued in due course. The move by the USFDA by itself is unlikely to change things immediately but in the longer term reflects its focus on ensuring accelerated drug approvals, which will translate into intensified pricing pressure even in complex drugs that are hitherto seen as the only secure...
Number of Mutual Funds holding stock rose by 12 to 235 in Sep 2017 qtr.
Aurobindo Pharma Limited    
26 Sep 2017
757.25
-0.77%
Cheap drugs pay for Aurobindo Pharma as USFDA approvals surge
Cheap drugs pay for Aurobindo Pharma as USFDA approvals surge
livemint
Aurobindo Pharma has not only had more products approved for sale by the US FDA than its largest Indian peers, but the number has often totaled more than that of its biggest 3 local rivals combined
Aurobindo Pharma Limited is trading above all available SMAs
Aurobindo Pharma Limited    
13 Sep 2017
757.25
-0.77%
Economic Times
The classification suggested that the matter has not escalated to the extent of slapping warnings letter or import alert.
Number of Mutual Funds holding stock rose by 12 to 235 in Sep 2017 qtr.
Aurobindo Pharma Limited    
01 Sep 2017
757.25
-0.77%
Geojit BNP Paribas
Better Q1FY18 performance compared to its peers Aurobindo Pharma (Auro) is one of the largest vertically integrated pharmaceutical companies. Over the past few years, the company has drastically shifted its focus...
Promoters pledge reduced to 1.22% of holdings in Jun 2017 qtr.
Aurobindo Pharma Limited    
24 Aug 2017
757.25
-0.77%
Nirmal Bang Institutional
We had a meeting with the management of Aurobindo Pharma (APL) recently to understand how it plans to further scale up its business in view of a growing revenue base that is witnessing rising pricing pressure in the US. The company clearly acknowledges these challenges and on an ongoing basis it is working towards ensuring that it is not over-dependent on any geography or product. Research and development or R&D; efforts which have been in place over the past several years has allowed it to create a superior product basket which is likely to face lower competition than its existing product...
Aurobindo Pharma Limited has an average target of 809.00 from 13 brokers.
Aurobindo Pharma Limited    
16 Aug 2017
757.25
-0.77%
Axis Direct
Gross margin improved 50 bps QoQ and EBITDA margin 170 bps QoQ on 8% QoQ growth in US sales and improving revenue mix (higher formulations and lower API/ ARV sales). However, PAT declined 11% YoY/ 3% QoQ on higher depreciation due to commissioning of new units.
Number of FIIs/FPIs holding stock rose by 6 to 775 in Sep 2017 qtr.
Aurobindo Pharma Limited    
14 Aug 2017
757.25
-0.77%
buy
Angel Broking
For 1QFY2018 Aurobindo Pharma (APL) posted numbers lower than expectations on sales, OPM and net profit fronts. On sales front, the company posted sales of `3621cr (v/s. `3,900cr expected) v/s. `3,664cr in 1QFY2017, posting a yoy de-growth of 1.2%. On the operating front, the EBITDA margin came in at 21.1% (v/s. 22.9% expected) v/s. 22.6%..
default
Aurobindo Pharma Limited has an average target of 809.00 from 13 brokers.
Aurobindo Pharma Limited    
11 Aug 2017
757.25
-0.77%
Khambatta Securities
Aurobindos revenues grew remained flat q-o-q and y-o-y at Rs 37,008 mn in 1Q FY18 falling short of our expectations. Revenue growth was dampened by poor offtake in ARV and API business during the quarter. API business was negatively impacted by destocking in lieu of GST implementation during the quarter. Adjusted EBITDA increased 16.2% q-o-q but decreased 4.5% y-o-y to Rs 8,637 mn during 1Q FY18. Adjusted EBITDA margin increased 306 bps q-o-q but decreased 58 bps y-o-y to 23.3% in 1Q FY18 mainly due to higher than expected Cost of...
Number of Mutual Funds holding stock rose by 12 to 235 in Sep 2017 qtr.
  • Stock Price (745.15) crossed above 30 Day SMA (734.67) on 12 October, 2017
  • Emkay increased Buy price target of Aurobindo Pharma Limited to 730.0 on 03 Oct, 2017.
  • Stock Price (742.20) crossed above 50 Day SMA (727.09) on 05 October, 2017
  • Stock Price (691.75) crossed above 100 Day SMA (681.95) on 29 September, 2017
  • Day volume (1454769) was 583% of the Month Average Volume (249397.0) on 26 September, 2017
More triggered alerts
Ex-Date Dividend Amount Dividend Type Record Date
June 8, 20171.25INTERIM-
Nov. 24, 20161.25INTERIM-
June 9, 20160.70INTERIM-
Feb. 18, 20160.70INTERIM-
Nov. 19, 20150.60INTERIM-
All dividends by AUROPHARMA
Ex-Date Dividend Bonus Ratio Record Date
July 20, 20151:1July 21, 2015
All bonuses by AUROPHARMA
Ex-Date Dividend Old FVNew FV Record Date
Feb. 10, 201151Feb. 11, 2011
All splits by AUROPHARMA